Comparing single‐agent with doublet chemotherapy in first‐line treatment of advanced non‐small cell lung cancer with performance status 2: A meta‐analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1743-7563|11|3|253-261

ISSN： 1743-7555

Source： ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.11, Iss.3, 2015-09, pp. : 253-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 710-718

Karger

Access to resources Recommend Favorite

Bevacizumab in combination with different platinum‐based doublets in the first‐line treatment for advanced nonsquamous non‐small‐cell lung cancer: A network meta‐analysis

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1676-1688

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inflammation‐Related Genetic Variations and Survival in Patients With Advanced Non–Small Cell Lung Cancer Receiving First‐Line Chemotherapy

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel as a Single Agent in First-Line Therapy of Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 16-17

Karger

Access to resources Recommend Favorite

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-08 ,pp. : 683-688

Karger

Access to resources Recommend Favorite